Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 27, 2026.

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction

Alexander Tenenbaum, Enrique Z Fisman

Cardiovascular Diabetology · 2012 · Review

doi:10.1186/1475-2840-11-125

Abstract

Currently the world faces epidemic of several closely related conditions: obesity, metabolic syndrome and type 2 diabetes (T2DM). The lipid profile of these patients and those with metabolic syndrome is characterized by the concurrent presence of qualitative as well as quantitative lipoprotein abnormalities: low levels of HDL, increased triglycerides, and prevalence of LDL particles that are smaller and denser than normal. This lipid phenotype has been defined as atherogenic dyslipidemia. Overwhelming evidences demonstrate that all components of the atherogenic dyslipidemia are important risk-factors for cardiovascular diseases. Optimal reduction of cardiovascular risk through comprehensive management of atherogenic dyslipidemias basically depends of the presence of efficacious lipid-modulating agents (beyond statin-based reduction of LDL-C). The most important class of medications which can be effectively used nowadays to combat atherogenic dyslipidemias is the fibrates. From a clinical point of view, in all available 5 randomized control trials beneficial effects of major fibrates (gemfibrozil, fenofibrate, bezafibrate) were clearly demonstrated and were highly significant in patients with atherogenic dyslipidemia. In these circumstances, the main determinant of the overall results of the trial is mainly dependent of the number of the included appropriate patients with atherogenic dyslipidemia. In a meta-analysis of dyslipidemic subgroups totaling 4726 patients a significant 35% relative risk reduction in cardiovascular events was observed compared with a non significant 6% reduction in those without dyslipidemia. However, different fibrates may have a somewhat different spectrum of effects. Currently only fenofibrate was investigated and proved to be effective in reducing microvascular complications of diabetes. Bezafibrate reduced the severity of intermittent claudication. Cardinal differences between bezafibrate and other fibrates are related to the effects on glucose metabolism and insulin resistance. Bezafibrate is the only clinically available pan - (alpha, beta, gamma) PPAR balanced activator. Bezafibrate decreases blood glucose level, HbA1C, insulin resistance and reduces the incidence of T2DM compared to placebo or other fibrates. Among major fibrates, bezafibrate appears to have the strongest and fenofibrate the weakest effect on HDL-C. Current therapeutic use of statins as monotherapy is still leaving many patients with atherogenic dyslipidemia at high risk for coronary events because even intensive statin therapy does not eliminate the residual cardiovascular risk associated with low HDL and/or high triglycerides. As compared with statin monotherapy (effective mainly on LDL-C levels and plaque stabilization), the association of a statin with a fibrate will also have a major impact on triglycerides, HDL and LDL particle size. Moreover, in the specific case of bezafibrate one could expect neutralizing of the adverse pro-diabetic effect of statins. Though muscle pain and myositis is an issue in statin/fibrate treatment, adverse interaction appears to occur to a significantly greater extent when gemfibrozil is administered. However, bezafibrate and fenofibrate seems to be safer and better tolerated. Combined fibrate/statin therapy is more effective in achieving a comprehensive lipid control and may lead to additional cardiovascular risk reduction, as could be suggested for fenofibrate following ACCORD Lipid study subgroup analysis and for bezafibrate on the basis of one small randomized study and multiple observational data. Therefore, in appropriate patients with atherogenic dyslipidemia fibrates- either as monotherapy or combined with statins - are consistently associated with reduced risk of cardiovascular events. Fibrates currently constitute an indispensable part of the modern anti-dyslipidemic arsenal for patients with atherogenic dyslipidemia.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 27, 2026. Paragraph numbers are ours, so an answer can point at one.

Atherogenic dyslipidemia

Currently the world faces epidemic of closely related conditions: obesity, metabolic syndrome and type 2 diabetes (T2DM). A strong correlation between T2DM and cardiovascular diseases is well established. Also for the metabolic syndrome (MetS) the best available evidence from randomized control trials (RCT) and large meta-analyses systematically had shown increased risk of cardiovascular events. The recent and largest meta-analysis included near one million patients (total n = 951,083). The investigators concluded that the MetS is associated with a 2-fold increase in cardiovascular outcomes and a 1.5-fold increase in all-cause mortality rates.

The lipid profile of patients with T2DM and MetS is characterized by the concurrent presence of qualitative as well as quantitative lipoprotein abnormalities: low levels of high density lipoprotein cholesterol (HDL-C) (<50 mg/dl in women, < 40 mg/dl in men), increased triglycerides (TG >150 mg/dl), and prevalence of low density lipoprotein (LDL) particles that are smaller and denser than normal (Figure 1). This lipid phenotype has been defined as atherogenic dyslipidemia. Interestingly, elevated LDL cholesterol (LDL-C) level is not typical of T2DM nor MetS. Overwhelming evidences demonstrate that all components of the atherogenic dyslipidemia are important risk-factors for cardiovascular diseases.

Particularly, a strong association exists between elevated triglycerides and cardiovascular disease. However, the extent to which triglycerides directly promote disease or represent a biomarker of risk has been debated for decades. The largest and most comprehensive recent meta-analysis included 29 prospective studies and 262,525 participants, proving a strong and highly significant association between triglycerides and coronary risk. Adjustment for HDL-C attenuated the magnitude but did not abolish the significant association between triglycerides and coronary risk. The triglyceride -rich environment has been shown to be strongly associated with an atherogenic lipoprotein phenotype or atherogenic dyslipidemia. In the United States, the National Health and Nutrition Examination Survey (NHANES) has monitored biomarkers of cardiovascular risk for 3 decades. Accordingly, increases in fasting serum triglyceride levels were observed between surveys conducted in 1976–1980 and 1999–2002. Also, nonfasting triglyceride strongly correlated with coronary risk. There is a broad agreement that reverse cholesterol transport, the process of transporting excess cholesterol from the arterial wall’s foam macrophages to the liver, bile, and feces is one of HDL’s important anti-atherogenic properties. Circulating HDL particles are greatly heterogeneous with a very complex metabolic profile. HDL-C measures the cholesterol content of nascent HDL, HDL2, and HDL3 particles and is, therefore, a crude marker of reverse cholesterol transport, whereas non-HDL-cholesterol is a valid marker of coronary risk.

Optimal reduction of cardiovascular risk through a comprehensive management of atherogenic dyslipidemias basically depends of the presence of efficacious lipid-modulating agents (beyond statin-based reduction of LDL-C). However, most of these agents are currently under serious concerns: niacin after negative AIM HIGH study and before HPS-2 THRIVE trial results, and cholesteryl ester transfer protein (CETP) -inhibitors and glitazars are still in controversial developments and not available for clinical use. Omega-3 polyunsaturated fatty acids supplementation seems to not really influence major cardiovascular outcomes. Therefore, the single class of medications which can be at the moment effectively used to combat atherogenic dyslipidemia beyond statins is only fibric acid derivatives - fibrates.

The role of fibrates in the management of atherogenic dyslipidemia

Fibrates are used in clinical practice for about half century due to their ability to substantially decrease triglyceride levels and increase HDL. All fibrates are peroxisome proliferators-activated receptors (PPARs) α agonists. Fibrates enhance the oxidation of fatty acids (FA) in liver and muscle and reduce the rate of hepatic lipogenesis, thereby reducing secretion of very-low-density lipoprotein (VLDL) triglycerides. The increased uptake of triglyceride-derived fatty acids in muscle cells results from an increase in lipoprotein lipase (LPL) activity in adjacent capillaries and a decrease in the apolipoprotein CIII (Apo CIII) concentration mediated transcriptionally by PPAR alpha. The decrease in apolipoprotein CIII reduces the inhibition of LPL activity. The enhanced catabolism of VLDL generates surface remnants, which are transferred to HDL. HDL concentrations are further augmented by an increase in PPARα - mediated transcription of apolipoprotein AI (Apo AI) and apolipoprotein AII (Apo AII). Ultimately, the rate of HDL-mediated reverse cholesterol transport may increase. Fibrates activate PPARα, which binds to a PPARα response element in conjunction with the retinoid X receptor. Other effects of fibrates include an increase in the size of LDL particles, increased removal of LDL, and a reduction in the levels of plasminogen activator inhibitor type I.

From a clinical point of view, in all available 5 randomized control trials (Table 1) the beneficial effects of major fibrates (gemfibrozil, fenofibrate, bezafibrate) were clearly demonstrated and were highly significant in patients with atherogenic dyslipidemia. For example, fenofibrate in the FIELD study: no significance in “general population”, already significant 14% risk reduction in low HDL subgroup, 23% significant risk reduction in high triglycerides subgroup and 27% significant risk reduction in patients with atherogenic dyslipidemia. In the earliest and the most successful Helsinki Heart Study with gemfibrozil, near all benefits were derived from the patients with atherogenic dyslipidemia without any impressive effects in other subgroups. The same is true for bezafibrate in the BIP trial, for fenofibrate in the ACCORD-Lipid trial and for gemfibrozil in the VA-HIT trial. We can see amazing similarity among all fibrates trials. In these circumstances, the key determinant of the overall results of the trial is dependent mainly on the number of the included appropriate patients with atherogenic dyslipidemia. So, in the ACCORD-Lipid trial there were only 17% appropriate patients with atherogenic dyslipidemia (941 of 5489)! In these patients 31% risk reductions was achieved (hazard ratio = 0.69, 95% confidence interval 0.49 - 0.97, p = 0.03 for within subgroup analysis, p for interaction = 0.057). However, 83% of patients in this trial were inappropriate for a fibrate treatment. Among them, the event rate was 10.1% in both treatment groups. Thus, overall results of the ACCORD-Lipid trial did not reach significance and this inappropriate patients selection lead to fail of the study.

In a recent meta-analysis of five dyslipidemic subgroups totaling 4726 patients, a 35% relative risk reduction in cardiovascular events was observed compared with a non significant 6% reduction in those without dyslipidemia. Meta-analysis performed in a so called “general population” reflecting a blend of effects in patients with and without atherogenic dyslipidemia - a “mean diluted” effect of fibrate therapy was reduced, producing only 13% RR reduction for coronary events (p < 0.0001). Figure 2 illustrates a dilution effect in epidemiology: strong significant cardiovascular risk reduction in patients with atherogenic dyslipidemia, non significant effect in those without dyslipidemia and blended modest effect in the mixed “general population”.

Therefore, in patients with atherogenic dyslipidemia (high triglycerides and low HDL-C), fibrates - either as monotherapy or combined with statins - are consistently associated with reduced risk of cardiovascular events. In patients without dyslipidemia this favorable effect - as expected - is absent.

Fibrates: different spectrum of effects

However, different fibrates may have a somewhat dissimilar spectrum of effects. Currently only fenofibrate was investigated in deep and proved to be effective in reducing microvascular complications of diabetes (in terms of diabetic retinopathy, progression of microalbuminuria and risk of limb amputations). However, there is no reason to suggest that other fibrates cannot do the same. The strongest hints for this were obtained in the large LEADER study when bezafibrate significantly reduced the severity of intermittent claudication for up to three years. In addition, bezafibrate effectively reduced microvascular complications in a experimental study. Also in the old RCTs, clofibrate was partially effective in the treatment of diabetic retinopathy due to an increased rate of absorption of hard exudates.

The underlying mechanisms of these effects are not fully elucidated. The reductions in the risk of T2DM-related retinopathy and risk of amputation with fenofibrate were apparently independent of effects on lipid parameters. The leading hypothesis included activation of PPARα which can modulate angiogenesis through a mechanism dependent on vascular endothelial growth factor. Actions arising via PPARα activation are likely to be shared between all fibric acid derivatives. Alternatively, influence on endothelial function, anti-inflammatory and anti-apoptotic effects and decreased circulating levels of fibrinogen could be involved.

Cardinal differences between bezafibrate and other fibrates are related to effects on glucose metabolism and insulin resistance. Bezafibrate, in contrast to other fibrates is pan - (alpha, beta, gamma) PPAR balanced activator. Bezafibrate leads to long-term stabilization of insulin sensitivity and pancreatic beta-cell function, reduced blood glucose level and HbA1C. In addition, bezafibrate significantly increased serum adiponectin level. Multiple studies have shown that bezafibrate reduced the incidence of T2DM by 30-40% compared to placebo or other fibrates during a long-term follow-up period.

In patients with MetS, bezafibrate treatment was associated with significant 29% reduced risk of any MI and 33% reduced risk of non-fatal MI. The early decrease in MI incidence was reflected later in a tendency of reduced cardiac mortality. Of note, among patients with augmented features of MetS (4–5 risk factors for MetS) a marked 56% reduction in cardiac mortality on bezafibrate was observed. Of course, caution should be used in interpreting these findings, which were identified in a post-hoc analysis.

What is the place of fibrates in the statins world?

Until now, there were no direct “head to head” statin vs. fibrate comparisons at all. Only recently intermediate-size (274 patients) RCT have demonstrated that bezafibrate was significantly better than pravastatin (a relatively weak statin) in reduction of cardiovascular events. Anyway, even intensive statin therapy does not eliminate the cardiovascular risk associated with low HDL or/and high triglycerides (atherogenic dyslipidemia)! Current therapeutic use of statins as monotherapy is still leaving many patients with combined dyslipidemia (which included atherogenic dyslipidemia) at high residual risk for coronary events. Figure 3A is a graphic representation of the definition of residual cardiovascular risk in patients treated by conventional statin therapy. The significant residual cardiovascular risk is still present and is not affected by standard LDL - lowering therapy.

The next step in the risk reduction was the concept of “intensive” high dose statin therapy. Direct testing of varying degrees (intensive vs. conventional) of LDL-C lowering by using of active comparators (statin vs. statin) has been tested in 5 large outcomes trials: PROVE IT--TIMI 22, A to Z, TNT, IDEAL and SEARCH. Out of the 5 trials which investigated intensive vs. standard statin regime, we have 2 “positive” with strong reservations: PROVE IT-TIMI 22 (it was based on very strange study design) and TNT (total death moved in a wrong direction) - and 3 “negative”: A to Z, IDEAL and SEARCH. Anyway, pooled data were in favour of the intensive statin therapy. Figure 3B illustrates the hypothetical extra benefit obtained by intensive statin therapy based on the meta-analysis (represented by the white box). Residual risk is still remained considerable. Significant increase in side effects during intensive therapy was observed (elevations of liver enzymes, muscle aches, cognitive decline and the development of diabetes mellitus).

The risk associated with high triglycerides and low HDL may be eliminated by fibrate. Among major fibrates, bezafibrate appears to have the strongest and fenofibrate the weakest effect on HDL-C (Figure 4). As compared with statin monotherapy (effective mainly on LDL-C levels and plaque stabilization), the association of a statin with a fibrate will also have a major impact on triglycerides, HDL and LDL particle size. Moreover, in the case of bezafibrate one could expect neutralizing of the adverse pro-diabetic effect of statins. Though muscle pain and myositis is an issue in statin/fibrate treatment, adverse interaction appears to occur to a significantly greater extent when gemfibrozil is administered. However, bezafibrate and fenofibrate seem to be safer and better tolerated.

Particularly, plasma concentration of statins are markedly increased by gemfibrozil but not by fenofibrate or bezafibrate. So, gemfibrozil, which is a good “evidence-based” fibrate for monotherapy, apears to be a problematic in the “statins world”. Unfortunately, safety concerns about gemfibrozil may lead to exaggerate precautions regarding fibrate administration and therefore diminish the use of these useful agents.

In a fibrate/statin combined therapy, the statin should probably be taken at the evening and the fibrate in the morning to avoid matched peak dose concentrations. Anyway, although in clinical trials the rate of adverse events on combination was not significantly greater compared with monotherapy, clinical and laboratory monitoring of patients who receive combined treatment could be prudent.

Currently there are a few hard outcome evidences regarding a combination statin/fibrate. In ACCORD Lipid study fenofibrate leads to cardiovascular risk reduction in pre-specified subgroup of patients with atherogenic dyslipidemia. In the observational study of the 150 patients, the combination of bezafibrate and simvastatin was more effective than monotherapy in reduction of cardiovascular events. In the small randomized controlled trial bezafibrate on top of statin-based treatment was a safe and significantly reduced major adverse cardiovascular events (MACE) in patients with acute ST elevation MI. The authors particularly emphasized in this study ability of bezafibrate significantly reduced fibrinogen levels.

Recently, new data regarding statin/fibrate combination were published using the high quality comprehensive nationwide ACSIS registry. There were 8545 patients treated with statin alone and 437 patients treated with a statin/fibrate combination (mainly bezafibrate). Development of 30-day MACE (primary end-point) was recorded in 6.0% patients from the statin monotherapy group vs. 3.2% from the combination group, (p = 0.01). 30-day re-hospitalization rate was also significantly lower in the combination group. Kaplan-Meier analysis of total mortality during one year was close to significance in favor of the combination (p = 0.066). Multivariate analysis identified the fibrate/statin combination as an independent predictor of 46% reduced risk of MACE in overall population (p = 0.03). In the subgroup interaction analysis the most impressive results were found in the subgroup with diabetes and atherogenic dyslipidemia. As one could expect, in patients without dyslipidemia this effect was absent. It should be emphasized that even though these “real world” observation data cannot replace RCT, the consistency of the results supports their credibility.

Conclusions

Even intensive statin therapy does not eliminate the residual cardiovascular risk associated with atherogenic dyslipidemia (low HDL and high triglycerides). Meta-analyses of randomized control trials clearly demonstrated that the main fibrates significantly reduce this risk. Combined fibrate/statin therapy is more effective in achieving a comprehensive lipid control and may lead to additional cardiovascular risk reduction, as could be suggested for fenofibrate following ACCORD Lipid study subgroup analysis and for bezafibrate on the bais on one small randomized study and multiple observational data. Therefore, in appropriate patients with atherogenic dyslipidemia fibrates- either as monotherapy or combined with statins – are consistently associated with reduced risk of cardiovascular events. Fibrates currently are an indispensable part of the modern anti-dyslipidemic arsenal for patients with atherogenic dyslipidemia.

Abbreviations

ACSIS: Acute Coronary Syndromes-Israel Survey; BIP: Bezafibrate Infarction Prevention study; CETP: Cholesteryl ester transfer protein; CHD: Coronary heart disease; FA: Fatty acids; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; LPL: Lipoprotein lipase; MACE: Major adverse cardiovascular events; MI: Myocardial infarction; PPARs: Peroxisome proliferators-activated receptors; RCT: The randomized control trials; VLDL: Very-low-density lipoprotein.

Competing interests

AT received speaker fee and travel expenses support from Abbott, Tribute, Novartis and Merck. EZF declares that he has no competing interests.

Authors’ contribution

Both authors have equally contributed in the conception and drafting of the manuscript. Both authors read and approved the final manuscript.

References 95

  1. 1.

    Brown M Byatt T Marsh T McPherson K National heart forum: micro simulation of obesity trends 2006 – 2050: obesity trends for adults analysis from the health survey for England 1993 – 2007 February 20102010 National Heart Forum, Londonhttp://nhfshare.heartforum.org.uk/RMAssets/NHFreports/NHF_adultobese_short_170210.pdf (Accessed October 1 2012)

    Not in our library

  2. 2.

    National Diabetes Information Clearinghouse (NDIC)Diabetes overview. NIH publication No. 09–38732008 http://diabetes.niddk.nih.gov/dm/pubs/overview/ (Accessed October 1 2012)

    Not in our library

  3. 3.

    van Vliet M Heymans MW von Rosenstiel IA Brandjes DP Beijnen JH Diamant M Cardiometabolic risk variables in overweight and obese children: a worldwide comparisonCardiovasc Diabetol2011 10106

    Not in our library10.1186/1475-2840-10-106

  4. 4.

    Tenenbaum A Motro M Schwammenthal E Fisman EZ Macrovascular complications of metabolic syndrome: an early intervention is imperativeInt J Cardiol2004 97167172

    Not in our library10.1016/j.ijcard.2003.07.033

  5. 5.

    Centers for Disease Control and PreventionNational Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 20112011 U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta

    Not in our library

  6. 6.

    Tenenbaum A Fisman EZ “The metabolic syndrome… is dead”: these reports are an exaggerationCardiovasc Diabetol2011 1011

    Not in our library10.1186/1475-2840-10-11

  7. 7.

    Haffner SM Lehto S Rönnemaa T Pyörälä K Laakso M Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarctionN Engl J Med1998 339229234

    Not in our library10.1056/nejm199807233390404

  8. 8.

    Donahoe SM Stewart GC McCabe CH Mohanavelu S Murphy SA Cannon CP Antman EM Diabetes and mortality following acute coronary syndromesJAMA2007 298765775

    Not in our library10.1001/jama.298.7.765

  9. 9.
    Estimated incidence of cardiovascular complications related to type 2 diabetes in Mexico using the UKPDS outcome model and a population-based survey · 2011
    Not checked
  10. 10.

    Gami AS Witt BJ Howard DE Erwin PJ Gami LA Somers VK Montori VM Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studiesJ Am Coll Cardiol2007 49403414

    Not in our library10.1016/j.jacc.2006.09.032

  11. 11.

    Galassi A Reynolds K He J Metabolic syndrome and risk of cardiovascular disease: a meta-analysisAm J Med2006 119812819

    Not in our library10.1016/j.amjmed.2006.02.031

  12. 12.

    Mottillo S Filion KB Genest J Joseph L Pilote L Poirier P Rinfret S Schiffrin EL Eisenberg MJ The metabolic syndrome and cardiovascular risk. A systematic review and meta-analysisJ Am Coll Cardiol2010 5611131132

    Not in our library10.1016/j.jacc.2010.05.034

  13. 13.
    Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial · 2011
    Not checked
  14. 14.

    Ninomiya JK L’Italien G Criqui MH Whyte JL Gamst A Chen RS Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination SurveyCirculation2004 1094246

    Not in our library10.1161/01.cir.0000116602.10533.2e

  15. 15.

    Austin MA Breslow JL Hennekens CH Buring JE Willett WC Krauss RM Low-density lipoprotein subclass patterns and risk of myocardial infarctionJAMA1988 26019171921

    Not in our library10.1001/jama.1988.03410130125037

  16. 16.

    Austin MA King MC Vranizan KM Krauss RM Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease riskCirculation1990 82495506

    Not in our library10.1161/01.cir.82.2.495

  17. 17.

    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.Circulation2002 10631433421

    Not in our library

  18. 18.

    Tenenbaum A Fisman EZ Motro M Adler Y Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statinsCardiovasc Diabetol2006 520

    Not in our library10.1186/1475-2840-5-20

  19. 19.

    Ghandehari H Kamal-Bahl S Wong ND Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003–2004Am Heart J2008 156112119

    Not in our library10.1016/j.ahj.2008.03.005

  20. 20.

    Rizzo M Berneis K Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?J Atheroscler Thromb2005 12237239

    Not in our library10.5551/jat.12.237

  21. 21.

    Li C Ford ES Tsai J Zhao G Balluz LS Gidding SS Serum non-high-density lipoprotein cholesterol concentration and risk of death from cardiovascular diseases among U.S. adults with diagnosed diabetes: the Third National Health and Nutrition Examination Survey linked mortality studyCardiovasc Diabetol2011 1046

    Not in our library10.1186/1475-2840-10-46

  22. 22.

    Sarwar N Sandhu MS Ricketts SL Butterworth AS Di Angelantonio E Boekholdt SM Ouwehand W Watkins H Samani NJ Saleheen D Lawlor D Reilly MP Hingorani AD Talmud PJ Danesh J Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors CollaborationTriglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studiesLancet2010 37516341639

    Not in our library10.1016/s0140-6736(10)60545-4

  23. 23.

    Chaudhary R Likidlilid A Peerapatdit T Tresukosol D Srisuma S Ratanamaneechat S Sriratanasathavorn C Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery diseaseCardiovasc Diabetol2012 1136

    Not in our library10.1186/1475-2840-11-36

  24. 24.

    Chiang JK Lai NS Chang JK Koo M Predicting insulin resistance using the triglyceride-to-high-density lipoprotein cholesterol ratio in Taiwanese adultsCardiovasc Diabetol2011 1093

    Not in our library10.1186/1475-2840-10-93

  25. 25.

    Hopkins PN Wu LL Hunt SC Brinton EA Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery diseaseJ Am Coll Cardiol2005 4510031012

    Not in our library10.1016/j.jacc.2004.11.062

  26. 26.

    Sarwar N Danesh J Eiriksdottir G Sigurdsson G Wareham N Bingham S Boekholdt SM Khaw KT Gudnason V Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studiesCirculation2007 115450458

    Not in our library10.1161/circulationaha.106.637793

  27. 27.

    Miller M Stone NJ Ballantyne C Bittner V Criqui MH Ginsberg HN Goldberg AC Howard WJ Jacobson MS Kris-Etherton PM Lennie TA Levi M Mazzone T Pennathur S American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism Council on Arteriosclerosis, Thrombosis and Vascular Biology Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular DiseaseTriglycerides and cardiovascular disease: a scientific statement from the American Heart AssociationCirculation2011 12322922333

    Not in our library10.1161/cir.0b013e3182160726

  28. 28.

    Nordestgaard BG Benn M Schnohr P Tybjaerg-Hansen A Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and womenJAMA2007 298299308

    Not in our library10.1001/jama.298.3.299

  29. 29.

    Bansal S Buring JE Rifai N Mora S Sacks FM Ridker PM Fasting compared with nonfasting triglycerides and risk of cardiovascular events in womenJAMA2007 298309316

    Not in our library10.1001/jama.298.3.309

  30. 30.

    Mackey RH Greenland P Goff DC Jr Lloyd-Jones D Sibley CT Mora S High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events: MESA (Multi-Ethnic Study of Atherosclerosis)J Am Coll Cardiol2012 60508516

    Not in our library10.1016/j.jacc.2012.03.060

  31. 31.

    Goldenberg I Boyko V Tennenbaum A Tanne D Behar S Guetta V Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trialArch Intern Med2009 169508514

    Not in our library10.1001/archinternmed.2008.584

  32. 32.

    Manninen V Elo MO Frick MH Haapa K Heinonen OP Heinsalmi P Helo P Huttunen JK Kaitaniemi P Koskinen P Mäenpää H Mälkönen M Mänttäri M Norola S Pasternack A Pikkarainen J Romo M Sjöblom T Nikkilä ES Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart StudyJAMA1988 260641651

    Not in our library10.1001/jama.1988.03410050061031

  33. 33.

    Hermans MP Sacks FM Ahn SA Rousseau MF Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalenceCardiovasc Diabetol2011 1020

    Not in our library10.1186/1475-2840-10-20

  34. 34.

    Natarajan P Ray KK Cannon CP High-density lipoprotein and coronary heart disease: current and future therapiesJ Am Coll Cardiol2010 5512831299

    Not in our library10.1016/j.jacc.2010.01.008

  35. 35.

    Boden WE Probstfield JL Anderson T Chaitman BR Desvignes-Nickens P Koprowicz K McBride R Teo K Weintraub W AIM-HIGH InvestigatorsNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med2011 36522552267

    Not in our library10.1056/nejmoa1107579

  36. 36.

    Rizos EC Ntzani EE Bika E Kostapanos MS Elisaf MS Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysisJAMA2012 30810241033

    Not in our library10.1001/2012.jama.11374

  37. 37.

    Knopp RH Drug treatment of lipid disordersN Engl J Med1999 341498511

    Not in our library10.1056/nejm199908123410707

  38. 38.

    Tenenbaum A Fisman EZ Motro M Adler Y Optimal management of combined dyslipidemia: what have we behind statins monotherapy?Adv Cardiol2008 45127153

    Not in our library10.1159/000115192

  39. 39.

    ACCORD Study GroupEffects of combination lipid therapy in type 2 diabetes mellitusN Engl J Med2010 36215631574

    Not in our library10.1056/nejmoa1001282

  40. 40.
    "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study · 2010
    Not checked
  41. 41.

    Scott R O’Brien R Fulcher G Pardy C D’Emden M Tse D Taskinen MR Ehnholm C Keech A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study InvestigatorsEffects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) studyDiabetes Care2009 32493498

    Not in our library10.2337/dc08-1543

  42. 42.

    The BIP Study GroupSecondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) studyCirculation2000 1022127

    Not in our library10.1161/01.cir.102.1.21

  43. 43.

    Manninen V Tenkanen L Koskinen P Huttunen JK Mänttäri M Heinonen OP Frick MH Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatmentCirculation1992 853745

    Not in our library10.1161/01.cir.85.1.37

  44. 44.

    Robins SJ Collins D Wittes JT Papademetriou V Deedwania PC Schaefer EJ McNamara JR Kashyap ML Hershman JM Wexler LF Rubins HB VA-HIT Study GroupRelation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trialJAMA2001 28515851591

    Not in our library10.1001/jama.285.12.1585

  45. 45.

    Keech A Simes RJ Barter P Best J Scott R Taskinen MR Forder P Pillai A Davis T Glasziou P Drury P Kesäniemi YA Sullivan D Hunt D Colman P d’Emden M Whiting M Ehnholm C Laakso M FIELD study investigatorsEffects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialLancet2005 36618491861

    Not in our library10.1016/s0140-6736(05)67667-2

  46. 46.

    Sacks FM Carey VJ Fruchart JC Combination lipid therapy in type 2 diabetesN Engl J Med2010 363692694

    Not in our library10.1056/nejmc1006407

  47. 47.

    Jun M Foote C Lv J Neal B Patel A Nicholls SJ Grobbee DE Cass A Chalmers J Perkovic V Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysisLancet2010 37518751878

    Not in our library10.1016/s0140-6736(10)60656-3

  48. 48.

    Meade T Zuhrie R Cook C Cooper J Bezafibrate in men with lower extremity arterial disease: randomised controlled trialBMJ2002 32573731139

    Not in our library10.1136/bmj.325.7373.1139

  49. 49.

    Khazaei M Salehi E Rashidi B Pan-PPAR agonist, bezafibrate, restores angiogenesis in hindlimb ischemia in normal and diabetic ratsInt J Pept2012 2012637212

    Not in our library10.1155/2012/637212

  50. 50.

    Harrold BP Marmion VJ Gough KR A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathyDiabetes1969 18285391

    Not in our library10.2337/diab.18.5.285

  51. 51.

    Duncan LJ Cullen JF Ireland JT Nolan J Clarke BF Oliver MF A three-year trial of atromid therapy in exudative diabetic retinopathyDiabetes1968 17458467

    Not in our library10.2337/diab.17.7.458

  52. 52.

    Hermans MP Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORDDiab Vasc Dis Res2011 8180189

    Not in our library10.1177/1479164111407783

  53. 53.

    Kim J Ahn JH Kim JH Yu YS Kim HS Ha J Shinn SH Oh YS Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathwayExp Eye Res2007 84886893

    Not in our library10.1016/j.exer.2007.01.009

  54. 54.
    Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons · 2005
    No notice
  55. 55.

    Willson TM Brown PJ Sternbach DD Henke BR The PPARs: from orphan receptors to drug discoveryJ Med Chem2000 43527550

    Not in our library10.1021/jm990554g

  56. 56.

    Tenenbaum A Fisman EZ Boyko V Benderly M Tanne D Haim M Matas Z Motro M Behar S Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrateArch Intern Med2006 166737741

    Not in our library10.1001/archinte.166.7.737

  57. 57.

    Ogawa S Takeuchi K Sugimura K Fukuda M Lee R Ito S Sato T Bezafibrate reduces blood glucose in type 2 diabetes mellitusMetabolism2000 49331334

    Not in our library10.1016/s0026-0495(00)90176-8

  58. 58.

    Tenenbaum H Behar S Boyko V Adler Y Fisman EZ Tanne D Lapidot M Schwammenthal E Feinberg M Matas Z Motro M Tenenbaum A Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetesAtherosclerosis2007 194265271

    Not in our library10.1016/j.atherosclerosis.2006.08.005

  59. 59.

    Teramoto T Shirai K Daida H Yamada N Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT studyCardiovasc Diabetol2012 1129

    Not in our library10.1186/1475-2840-11-29

  60. 60.

    Hiuge A Tenenbaum A Maeda N Benderly M Kumada M Fisman EZ Tanne D Matas Z Hibuse T Fujita K Nishizawa H Adler Y Motro M Kihara S Shimomura I Behar S Funahashi T Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin levelArterioscler Thromb Vasc Biol2007 27635644

    Not in our library10.1161/01.atv.0000256469.06782.d5

  61. 61.

    Tenenbaum A Motro M Fisman EZ Schwammenthal E Adler Y Goldenberg I Leor J Boyko V Mandelzweig L Behar S Peroxisome proliferator-activated receptors ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery diseaseCirculation2004 10921972202

    Not in our library10.1161/01.cir.0000126824.12785.b6

  62. 62.

    Tenenbaum A Motro M Fisman EZ Adler Y Shemesh J Tanne D Leor J Boyko V Schwammenthal E Behar S Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patientsEur Heart J2005 2620322038

    Not in our library10.1093/eurheartj/ehi310

  63. 63.

    Flory JH Ellenberg S Szapary PO Strom BL Hennessy S Antidiabetic action of bezafibrate in a large observational databaseDiabetes Care2009 32547551

    Not in our library10.2337/dc08-1809

  64. 64.

    Tenenbaum A Motro M Fisman EZ Tanne D Boyko V Behar S Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndromeArch Intern Med2005 16511541160

    Not in our library10.1001/archinte.165.10.1154

  65. 65.

    Sano K Nakamura T Hirano M Kitta Y Kobayashi T Fujioka D Saito Y Yano T Watanabe K Watanabe Y Mishina H Obata JE Kawabata K Kugiyama K Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoproteinCirc J2010 7416441650

    Not in our library10.1253/circj.cj-10-0079

  66. 66.

    Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet2002 36072212114036

    Not in our library

  67. 67.

    Sacks FM Tonkin AM Shepherd J Braunwald E Cobbe S Hawkins CM Keech A Packard C Simes J Byington R Furberg CD for the Prospective Pravastatin Pooling ProjectEffect of pravastatin on coronary disease events in subgroups defined by coronary risk factorsCirculation2000 10218931900

    Not in our library10.1161/01.cir.102.16.1893

  68. 68.

    Ballantyne CM Herd JA Ferlic LL Dunn JK Farmer JA Jones PH Schein JR Gotto AM Jr Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapyCirculation1999 99736743

    Not in our library10.1161/01.cir.99.6.736

  69. 69.

    Scandinavian Simvastatin Survival Study GroupBaseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)Lancet1995 34512741275

    Not in our library

  70. 70.

    The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study GroupPrevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levelsN Engl J Med1998 33913491357

    Not in our library10.1056/nejm199811053391902

  71. 71.

    Pfeffer MA Sacks FM Moyé LA East C Goldman S Nash DT Rouleau JR Rouleau JL Sussex BA Theroux P Vanden Belt RJ Braunwald E Influence of baseline lipids on effectiveness of pravastatin in the CARE trialJ Am Coll Cardiol1999 33125130

    Not in our library10.1016/s0735-1097(98)00522-1

  72. 72.

    Shepherd J Cobbe SM Ford I Isles CG Lorimer AR MacFarlane PW McKillop JH Packard CJ Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study GroupN Engl J Med1995 33313011307

    Not in our library10.1056/nejm199511163332001

  73. 73.

    Downs JR Clearfield M Weis S Whitney E Shapiro DR Beere PA Langendorfer A Stein EA Kruyer W Gotto AM Jr Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPSJAMA1998 27916151622

    Not in our library10.1001/jama.279.20.1615

  74. 74.

    Chapman MJ Redfern JS McGovern ME Giral P Optimal pharmacotherapy to combat the atherogenic lipid triadCurr Opin Cardiol2011 26403411

    Not in our library10.1097/hco.0b013e32834965e9

  75. 75.

    Cannon CP Braunwald E McCabe CH Rader DJ Rouleau JL Belder R Joyal SV Hill KA Pfeffer MA Skene AM Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: intensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med2004 35014951504

    Not in our library10.1056/nejmoa040583

  76. 76.

    de Lemos JA Blazing MA Wiviott SD Lewis EF Fox KA White HD Rouleau JL Pedersen TR Gardner LH Mukherjee R Ramsey KE Palmisano J Bilheimer DW Pfeffer MA Califf RM Braunwald E A to Z InvestigatorsEarly intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trialJAMA2004 29213071316

    Not in our library10.1001/jama.292.11.1307

  77. 77.

    LaRosa JC Grundy SM Waters DD Shear C Barter P Fruchart JC Gotto AM Greten H Kastelein JJ Shepherd J Wenger NK Treating to New Targets (TNT) Investigators: intensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med2005 35214251435

    Not in our library10.1056/nejmoa050461

  78. 78.

    Pedersen TR Faergeman O Kastelein JJ Olsson AG Tikkanen MJ Holme I Larsen ML Bendiksen FS Lindahl C Szarek M Tsai J Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study GroupHigh-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trialJAMA2005 29424372445

    Not in our library10.1001/jama.294.19.2437

  79. 79.

    Armitage J Bowman L Wallendszus K Bulbulia R Rahimi K Haynes R Parish S Peto R Collins R Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative GroupIntensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trialLancet2010 37616581669

    Not in our library10.1016/s0140-6736(10)60310-8

  80. 80.

    Cannon CP Steinberg BA Murphy SA Mega JL Braunwald E Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapyJ Am Coll Cardiol2006 48438445

    Not in our library10.1016/j.jacc.2006.04.070

  81. 81.

    Wagstaff LR Mitton MW Arvik BM Doraiswamy PM Statin-associated memory loss: analysis of 60 case reports and review of the literaturePharmacotherapy2003 23871880

    Not in our library10.1592/phco.23.7.871.32720

  82. 82.

    Muldoon MF Ryan CM Sereika SM Flory JD Manuck SB Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adultsAm J Med2004 117823829

    Not in our library10.1016/j.amjmed.2004.07.041

  83. 83.

    Culver AL Ockene IS Balasubramanian R Olendzki BC Sepavich DM Wactawski-Wende J Manson JE Qiao Y Liu S Merriam PA Rahilly-Tierny C Thomas F Berger JS Ockene JK Curb JD Ma Y Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health InitiativeArch Intern Med2012 172144152

    Not in our library10.1001/archinternmed.2011.625

  84. 84.

    Jones PH Davidson MH Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statinAm J Cardiol2005 95120122

    Not in our library10.1016/j.amjcard.2004.08.076

  85. 85.

    Fruchart JC Sacks F Hermans MP Assmann G Brown WV Ceska R Chapman MJ Dodson PM Fioretto P Ginsberg HN Kadowaki T Lablanche JM Marx N Plutzky J Reiner Z Rosenson RS Staels B Stock JK Sy R Wanner C Zambon A Zimmet P The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemiaAm J Cardiol2008 1021K34K

    Not in our library10.1016/j.amjcard.2008.10.002

  86. 86.

    Farnier M Combination Therapy with an HMG-CoA Reductase Inhibitor and a Fibric Acid Derivative: a Critical Review of Potential Benefits and DrawbacksAm J Cardiovasc Drugs2003 3169178

    Not in our library10.2165/00129784-200303030-00003

  87. 87.

    Shek A Ferrill MJ Statin-fibrate combination therapyAnn Pharmacother2001 35908917

    Not in our library10.1345/aph.10315

  88. 88.

    Prueksaritanont T Tang C Qui Y Mu L Subramanian R Lin JH Effects of fibrates on metabolism of statins in human hepatocytesDrug Metab Dispos2002 3012801287

    Not in our library10.1124/dmd.30.11.1280

  89. 89.

    Backman JT JT Kyrklund C Kivistö KT Wang JS Neuvonen PJ Plasma concentrations of active simvastatin acid are increased by gemfibrozilClin Pharmacol Ther2000 68122129

    Not in our library10.1067/mcp.2000.108507

  90. 90.

    Kyrklund C Backman JT Kivistö KT Neuvonen M Laitila J Neuvonen PJ Plasma conentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrateClin Pharmacol Ther2001 69340345

    Not in our library10.1067/mcp.2001.115542

  91. 91.

    Kehely A MacMahon M Barbir M Wray R Hunt BJ Prescott RJ Thompson GR Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemiaQJM1995 88421427

    Not in our library

  92. 92.

    Gavish D Leibovitz E Shapira I Rubinstein A Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safetyJ Intern Med2000 247563569

    Not in our library10.1046/j.1365-2796.2000.00646.x

  93. 93.

    Bergman AJ Murphy G Burke J Zhao JJ Valesky R Liu L Lasseter KC He W Prueksaritanont T Qiu Y Hartford A Vega JM Paolini JF Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humansJ Clin Pharmacol2004 4410541062

    Not in our library10.1177/0091270004268044

  94. 94.

    Madrid-Miller A Moreno-Ruiz LA Borrayo-Sánchez G Almeida-Gutiérrez E Martínez-Gómez DF Jáuregui-Aguilar R Impact of bezafibrate treatment in patients with hyperfibrinogenemia and ST-elevation acute myocardial infarction: a randomized clinical trialCir Cir2010 78229237

    Not in our library

  95. 95.

    Tenenbaum A Medvedofsky D Fisman EZ Bubyr L Matetzky S Tanne D Klempfner R Shemesh J Goldenberg I Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys dataPLoS One2012 74e35298

    Not in our library10.1371/journal.pone.0035298

Cited by papers we hold 5

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.